Related Experiment Video
Updated: May 19, 2026
Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Colchicine protects against hyperoxic lung injury in neonatal rats
Ramazan Ozdemir1, Sadık Yurttutan, Beril Talim
1Division of Neonatology, Department of Pediatrics, Turgut Özal Medical Center, Inönü University School of Medicine, Malatya, Turkey. ramazanoz@yahoo.com.tr
Insights
Colchicine treatment reduced lung damage and inflammation in an animal model of bronchopulmonary dysplasia (BPD). This study shows colchicine
Area of Science:
- Pulmonary Medicine
- Neonatology
- Pharmacology
Background:
- Bronchopulmonary dysplasia (BPD) is a chronic lung disease in infants characterized by inflammation, fibrosis, and alveolar damage.
- The condition leads to impaired lung development and long-term respiratory issues.
Purpose of the Study:
- To investigate the potential of colchicine, an anti-inflammatory and antioxidant drug, in mitigating lung injury in a BPD animal model.
- To assess colchicine's efficacy in reducing BPD-related inflammation, fibrosis, and oxidative stress.
Main Methods:
- Twenty-five rat pups were divided into control, hyperoxia, and hyperoxia + colchicine groups.
- Hyperoxia exposure simulated BPD conditions; lungs were analyzed for morphology (mean linear intercept), inflammation (TNF-α, IL-1β), and oxidative stress (MDA, SOD, GSH-Px).
Main Results:
- Colchicine significantly reduced lung damage, indicated by a lower mean linear intercept.
- Treatment with colchicine decreased levels of malondialdehyde (MDA) and inflammatory markers (TNF-α, IL-1β).
- Colchicine administration increased antioxidant enzyme activity (SOD, GSH-Px) in lung tissue.
Conclusions:
- Colchicine demonstrates beneficial effects on alveolar development in a BPD model.
- The drug effectively reduced inflammation and oxidative stress markers associated with BPD.
- Colchicine shows promise as a therapeutic agent for bronchopulmonary dysplasia.
Background:
Bronchopulmonary dysplasia (BPD) is characterized by inflammation, fibrosis and mucosal necrosis, which leads to emphysematous coalescence of alveoli.
Objective:
We tested whether prophylaxis with colchicine , an anti-inflammatory, antioxidant and antifibrotic drug, would decrease the severity of lung injury in an animal model of BPD.
Methods:
Twenty-five rat pups were divided into three groups: control (n = 8), hyperoxia (n = 7), and hyperoxia + colchicine (n = 10). The hyperoxia groups were exposed to >95% oxygen from day 1 to 10 of life. On day 10, the animals were sacrificed and the lungs were processed for histology and biochemical analysis. Lung morphology was assessed by the mean linear intercept (MLI), a measure of alveolar size. The degree of lung inflammation and antioxidant capacity were assessed by quantifying lung homogenate tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) levels.
Results:
Colchicine significantly decreased lung damage as determined by the MLI in the hyperoxia groups (p < 0.01). The median level of lung MDA was significantly higher in the hyperoxia group compared with the control group (p < 0.05) and the colchicine-treated group (p < 0.05). Lung homogenate SOD and GSH-Px activities in the colchicine-treated group were significantly higher than in the hyperoxia group (p < 0.05). Furthermore, colchicine-treated pups had lower lung homogenate TNF-α and IL-1β levels compared with the hyperoxia group (p < 0.05).
Conclusions:
Colchicine has favorable effects on alveolarization as well as inflammation and oxidative stress markers in an animal model of BPD.
